JENNIFER GRAHAM: Open Payments
NPI 1972796944 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$556 in 28 payments from 11 companies in 2025. Trend: 2023 $796 · 2024 $733 · 2025 $556
Food & beverage: $556
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $196 |
| Astellas Pharma US Inc | 4 | $131 |
| Novo Nordisk Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Janssen Biotech, Inc. | 1 | $20 |
| Organon LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: Veozah, VRAYLAR, UBRELVY, QULIPTA, REXULTI, Ozempic, SPRAVATO, Rybelsus.
Industry payments across NE — which companies pay providers there.
